Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Glioma 2Glioblastoma 2Cholangiocarcinoma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 10Radiotherapy 5Carboplatin 5Vincristine 4Radiosurgery 4Surveys and Questionnaires 3Magnetic Resonance Imaging 3Etoposide 3Bevacizumab 3etoposide phosphate 2Vorinostat 2Magnetic Resonance Spectroscopy 2Lomustine 2Irinotecan 2Immunoglobulin G 2Ifosfamide 2Fluorodeoxyglucose F18 2Disulfides 2Cisplatin 2veliparib 1tozuleristide 1romidepsin 1perillyl alcohol 1pembrolizumab 1olutasidenib 1lonafarnib 1ispinesib 1emvododstat 1cediranib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spinal Cord Neoplasms × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡